Contents

List of Contributors xi
Preface xv

1 Diagnosis and revision of the classification systems 1
   Assen Jablensky
   Introduction 1
   Origin and evolution of the concept of schizophrenia 2
      Kraepelin’s ‘clinical forms’ 3
      Bleuler’s ‘group of schizophrenias’ 4
      Leonhard’s ‘endogenous psychoses’ 5
      Classification of psychoses in French psychiatry 5
      Other post-Kraepelinian and post-Bleulerian subtypes and dichotomies 5
      The schizophrenia spectrum concept 8
      Statistically derived clusters and symptom dimensions 8
   Schizophrenia in ICD-10 and DSM-IV 9
      Origins of the two classifications 10
      Both DSM-IV and ICD-10 are descendants of the Kraepelinian nosology 10
      Criteria for assessing the diagnostic classification of schizophrenia 13
      Positive impact and unintended adverse effects 13
      Clinical relevance and cognitive ease of use 14
      Utility in research 15
      Reliability 16
      Concepts of validity 16
      Predictive validity: course and outcome 17
      Criterion validity: genetics 19
      Aspects of culture 21
      Reducing stigma 21
   Revision of the classifications: prospects for schizophrenia 22
      One classification or many? 22
Critical issues in the revision process 22
  Disease or a broad syndrome? 22
  ‘Deconstructing’ schizophrenia: categories or dimensions? 23
  Endophenotypes 23
  The concept of utility 24
Conclusion 25
References 26

2 Pathophysiology of schizophrenia 31
Peter Falkai, Andrea Schmitt and Tyrone D. Cannon
Introduction 31
Major findings and related pathophysiological hypotheses 32
  Symptom domains and neurotransmitter hypotheses 32
  From domains to disturbed neuronal networks 38
  From networks to the cellular level 42
  Hypothesis of disturbed synaptogenesis and neurogenesis 48
  Effects of antipsychotics 50
Summary and conclusions 51
References 51

3 Neurocognition, social cognition and functional outcome in schizophrenia 67
William P. Horan, Philippe-Olivier Harvey, Robert S. Kern and Michael F. Green
Introduction 67
Neurocognition in schizophrenia 68
  Domains, measurement and magnitude of impairment 69
  Neurocognition as a core deficit of schizophrenia 69
  Associations with functional outcome 71
  The NIMH-MATRICS initiative and current research directions 72
Social cognition 74
  Domains, measurement and magnitude of impairment 75
  Social cognition as a core feature of schizophrenia 79
  Association with functional outcome 80
  Current research directions 80
Relationships among neurocognition, social cognition and functional outcome 81
  Distinctiveness of neurocognition and social cognition 81
  Social cognition as a mediator 82
Future directions 91
References 95
## CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 The genetics of schizophrenia</td>
<td>109</td>
</tr>
<tr>
<td>James T.R. Walters, Michael O’Donovan, Michael J. Owen and Wolfgang Gaebel</td>
<td></td>
</tr>
<tr>
<td>Introduction</td>
<td>109</td>
</tr>
<tr>
<td>Genetic epidemiology of schizophrenia</td>
<td>110</td>
</tr>
<tr>
<td>Family, twin and adoption studies of schizophrenia</td>
<td>110</td>
</tr>
<tr>
<td>Genetic epidemiology – informing diagnosis?</td>
<td>111</td>
</tr>
<tr>
<td>Molecular genetics of schizophrenia</td>
<td>113</td>
</tr>
<tr>
<td>Linkage</td>
<td>114</td>
</tr>
<tr>
<td>Positional candidate studies</td>
<td>115</td>
</tr>
<tr>
<td>Functional candidate studies</td>
<td>116</td>
</tr>
<tr>
<td>Chromosomal abnormalities</td>
<td>120</td>
</tr>
<tr>
<td>Genome wide association studies</td>
<td>121</td>
</tr>
<tr>
<td>GWAS in schizophrenia</td>
<td>122</td>
</tr>
<tr>
<td>Copy number variation</td>
<td>126</td>
</tr>
<tr>
<td>The future of schizophrenia genetics</td>
<td>130</td>
</tr>
<tr>
<td>Schizophrenia genetics in the clinic?</td>
<td>133</td>
</tr>
<tr>
<td>Conclusions</td>
<td>134</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>134</td>
</tr>
<tr>
<td>References</td>
<td>134</td>
</tr>
<tr>
<td>5 Early recognition and prevention of schizophrenia</td>
<td>141</td>
</tr>
<tr>
<td>Patrick D. McGorry and Sherilyn Goldstone</td>
<td></td>
</tr>
<tr>
<td>The context for early recognition and prevention</td>
<td>141</td>
</tr>
<tr>
<td>The prodromal stage: definition and assessment</td>
<td>143</td>
</tr>
<tr>
<td>Treatment during the prodromal stage</td>
<td>146</td>
</tr>
<tr>
<td>The psychosis risk syndrome: a novel diagnostic entity?</td>
<td>150</td>
</tr>
<tr>
<td>Ethical issues</td>
<td>154</td>
</tr>
<tr>
<td>Summary and conclusions</td>
<td>155</td>
</tr>
<tr>
<td>References</td>
<td>156</td>
</tr>
<tr>
<td>6 Pharmacological treatment</td>
<td>161</td>
</tr>
<tr>
<td>Jonathan E. Sherin and Stephen R. Marder</td>
<td></td>
</tr>
<tr>
<td>Introduction</td>
<td>161</td>
</tr>
<tr>
<td>Current state of pharmacological treatment</td>
<td>162</td>
</tr>
<tr>
<td>Phases of schizophrenia</td>
<td>163</td>
</tr>
<tr>
<td>Acute phase treatment</td>
<td>163</td>
</tr>
<tr>
<td>Stabilization phase treatment</td>
<td>166</td>
</tr>
<tr>
<td>Maintenance phase treatment</td>
<td>166</td>
</tr>
<tr>
<td>Treatment resistant patients</td>
<td>167</td>
</tr>
<tr>
<td>Managing first episodes</td>
<td>168</td>
</tr>
<tr>
<td>Newer antipsychotics</td>
<td>168</td>
</tr>
</tbody>
</table>
CONTENTS

Personalising drug treatment in schizophrenia 169
Cognition and negative symptoms as therapeutic targets 170
Glutamatergic targets 171
Dopamine targets 172
Cholinergic targets 174
Histamine targets 176
Summary 178
References 178

7 Cognitive-behavioural interventions 185
Suzanne Jolley and Philippa Garety
Introduction 185
The development of cognitive behavioural approaches to schizophrenia-spectrum psychosis 186
Cognitive behavioural models of psychosis 186
Biopsychosocial vulnerability 186
Life events and schematic beliefs 187
The role of affect 188
The central role of appraisal 189
Reasoning biases 190
Anomalous experiences 191
The role of behaviour 192
Insight and illness appraisals 192
Cognitive behavioural therapy in schizophrenia 193
Psychotherapy in schizophrenia: more than unspecific learning? 196
Combining psychotherapy and pharmacotherapy 197
Efficacy of cognitive behavioural therapy for psychosis (CBTp) 198
Future developments 201
Conclusions 203
Acknowledgements 203
References 203

8 Management, rehabilitation, stigma 217
Wulf Rössler
Introduction 217
Managing schizophrenia: integrative approaches 218
Burden for patients, families and communities 218
Gender issues 220
Mortality 222
Legal problems 223
CONTENTS

Health care settings for schizophrenia patients: which setting is optimal? 225
Psychiatric rehabilitation 227
   The international classification of functioning, disability and health 227
   Target population 229
Conceptual framework 229
Current approaches 230
   Individual-centred rehabilitation 230
Cognitive behavioural therapy 231
Social skills training 232
   Ecological approach to rehabilitation 233
Housing 233
Work 234
Participation in community life with full rights 235
The contribution of mental health professionals to stigma and discrimination 237
The role of the psychiatrist in the management and rehabilitation of schizophrenia patients 238
Outlook 239
References 239

Index 247